34 Chapter 2 28. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. Journal of biomedical informatics. 2019;95:103208. https://doi.org/10.1016/j.jbi.2019.103208 29. Purohit S, Gupta P, Agarwal K, Sharma T, Durlabhji P, Sharma R. Glucose tolerance during rifampicin therapy. Ind J Tub. 1984;31:3. 30. Singh M, Biswas S, Shah A. Impaired glucose tolerance in active pulmonary tuberculosis. Indian J Tuberc. 1984;31(3):118-21. 31. Akinlade K, Rahamon S, Edem V, Ige O, Arinola O. Glycated haemoglobin levels in patients with multidrug-resistant tuberculosis infection during 6 months of treatment. African Journal of Clinical and Experimental Microbiology. 2016;17(3):173-8. https://doi.org/10.4314/ajcem.v17i3.3 32. Lin Y, Yuan Y, Zhao X, Liu J, Qiu L, He X, et al. The change in blood glucose levels in tuberculosis patients before and during anti-tuberculosis treatment in China. Global health action. 2017;10(1):1289737. https://doi.org/10.1080/16549716.2017.1289737 33. Moreira J, Castro R, Lamas C, Ribeiro S, Grinsztejn B, Veloso VG. Hyperglycemia during tuberculosis treatment increases morbidity and mortality in a contemporary cohort of HIV-infected patients in Rio de Janeiro, Brazil. International Journal of Infectious Diseases. 2018;69:11-9. https://doi. org/10.1016/j.ijid.2017.12.014 34. Diarra B, Tolofoudie M, Sarro Y, Togo A, Bane S, Nientao I, et al. Diabetes Mellitus among new tuberculosis patients in Bamako, Mali. Journal of clinical tuberculosis and other mycobacterial diseases. 2019;17:100128. https://doi.org/10.1016/j.jctube.2019.100128 35. Habib SS, Rafiq S, Jamal WZ, Ayub SM, Ferrand RA, Khan A, et al. Engagement of private healthcare providers for case finding of tuberculosis and diabetes mellitus in Pakistan. BMC health services research. 2020;20(1):1-8. https://doi.org/10.1186/s12913-020-05217-2 36. Kubjane M, Berkowitz N, Goliath R, Levitt NS, Wilkinson RJ, Oni T. Tuberculosis, Human Immunodeficiency Virus, and the Association With Transient Hyperglycemia in Periurban South Africa. Clinical Infectious Diseases. 2020;71(4):1080-8. https://doi.org/10.1093/cid/ciz928 37. Association AD. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes care. 2019;42(Supplement_1):S13-S28. https://doi.org/10.2337/dc19S002 38. Wang J-Y, Lee L, Hsueh P. Factors changing the manifestation of pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2005;9(7):777-83. 39. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease. 2019;23(7):783-96. https://doi.org/10.5588/ijtld.18.0433 40. Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Nogueira B, Freire MVC, Queiroz AT, et al. The Effect of Diabetes and Prediabetes on Antituberculosis Treatment Outcomes: A Multicenter Prospective Cohort Study. The Journal of Infectious Diseases. 2022;225(4):617-26. https://doi. org/10.1093/infdis/jiab427 41. Yorke E, Boima V, Dey ID, Amissah-Arthur M-B, Ganu V, Amaning-Kwarteng E, et al. Transient Impact of Dysglycemia on Sputum Conversion among Smear-Positive Tuberculosis Patients in a Tertiary Care Facility in Ghana. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. 2021;15:11795484211039830. https://doi.org/10.1177/11795484211039830 42. Faurholt-Jepsen D, Range N, PrayGod G, Jeremiah K, Faurholt-Jepsen M, Aabye MG, et al. Diabetes is a risk factor for pulmonary tuberculosis: a case-control study from Mwanza, Tanzania. PloS one. 2011;6(8):e24215. https://doi.org/10.1371/journal.pone.0024215
RkJQdWJsaXNoZXIy MTk4NDMw